|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.69 CNY | -2.74% |
|
-0.30% | -2.23% |
| 03-19 | China Approves Raw Material Application for Yiling Pharmaceutical's Type 2 Diabetes Complications Drug | MT |
| 03-04 | Yiling Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug | MT |
Business description: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Number of employees: 11,708
Sales by Activity: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
Pharmaceutical Manufacturing | 8.78B | 10.12B | 12.53B | 10.32B | 6.51B |
Geographical breakdown of sales: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
China | 8.48B | 9.76B | 12.07B | 10.08B | 6.22B |
Foreign | 304M | 357M | 463M | 239M | 295M |
Executive Committee: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Xiang Jun Wu
CEO | Chief Executive Officer | 51 | 2013-03-31 |
Chen Guang Li
DFI | Director of Finance/CFO | 53 | 2018-04-23 |
Qiu Lian Zhang
PRN | Corporate Officer/Principal | 56 | 2020-01-15 |
Rui Wu
SEC | Corporate Secretary | 46 | 2010-08-30 |
Hua Wang
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Yi Ling Wu
CHM | Chairman | 77 | 2012-08-30 |
Xiang Jun Wu
BRD | Director/Board Member | 51 | 2010-08-30 |
Chen Guang Li
BRD | Director/Board Member | 53 | 2018-05-16 |
Xue Dong Gao
CHM | Chairman | 56 | 2014-08-18 |
Rui Hua Niu
BRD | Director/Board Member | 47 | 2009-02-28 |
Rui Wu
BRD | Director/Board Member | 46 | 2016-12-11 |
Wei Dong Xu
BRD | Director/Board Member | 58 | 2020-01-15 |
Gen Wu Liu
BRD | Director/Board Member | 53 | 2014-08-17 |
Zhen Wang
BRD | Director/Board Member | 53 | 2016-12-11 |
Qiu Lian Zhang
BRD | Director/Board Member | 56 | 2015-03-15 |
Company details: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
No. 238 Tianshan Avenue
050035, Shijiazhuang
+86 40 0789 8989
http://www.yiling.cn
Alternative Medicine
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.74% | -0.30% | +26.15% | -46.88% | 4.09B | |
| -0.41% | +0.67% | -3.56% | -0.90% | 14.47B | |
| -0.75% | -0.25% | -23.69% | -49.58% | 5.58B | |
| -2.88% | -1.33% | -14.64% | +3.94% | 5.09B | |
| -1.09% | -1.02% | +35.76% | +1.55% | 4.06B | |
| -1.35% | -0.92% | -5.57% | -23.22% | 3.37B | |
| -1.18% | +0.78% | -6.00% | -8.30% | 3.12B | |
| -1.07% | -0.12% | +14.87% | -18.55% | 2.58B | |
| -0.60% | -0.13% | -3.52% | -12.83% | 1.95B | |
| -0.75% | -2.77% | -8.19% | +26.68% | 1.74B | |
| Average | -1.28% | +0.79% | +1.16% | -12.81% | 4.6B | |
| Weighted average by Cap. | -1.17% | +0.78% | -0.58% | -12.71% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 002603 Stock
- Company Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition